Crescent Biopharma, Inc. (CBIO) |
| 12.09 -0.255 (-2.07%) 02-27 16:00 |
| Open: | 12.2 |
| High: | 12.32 |
| Low: | 11.4912 |
| Volume: | 135,298 |
| Market Cap: | 333(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 16.32 |
| Resistance 1: | 13.97 |
| Pivot price: | 10.63 |
| Support 1: | 10.73 |
| Support 2: | 8.72 |
| 52w High: | 29 |
| 52w Low: | 8.72 |
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Financials
| EPS | 0.000 |
| Book Value | 5.760 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Fri, 27 Feb 2026
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Thu, 26 Feb 2026
Crescent Biopharma: Q4 Earnings Snapshot - theheraldreview.com
Thu, 26 Feb 2026
Crescent Biopharma: Q4 Earnings Snapshot - Eagle-Tribune
Thu, 26 Feb 2026
CBIO: Expanded oncology pipeline and strong cash position support multiple clinical milestones into 2028 - TradingView
Thu, 26 Feb 2026
Crescent Biopharma (Nasdaq: CBIO) ramps R&D with $185M raise and 2025 loss - Stock Titan
Thu, 26 Feb 2026
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
